|D011660||Pulmonary Heart Disease NIH||1.00|
|D006333||Heart Failure NIH||0.33|
There is one clinical trial.
Although COVID-19 affects primarily the respiratory system, several studies have shown evidence of cardiovascular alterations. Increased troponin levels were observed in a significant proportion of patients and this alteration was associated with higher mortality. In addition, case reports of cardiogenic shock or fulminant myocarditis have been communicated. Likewise, pulmonary embolism (PE), right ventricle dilation, and acute cor pulmonale (ACP) have also been described. Therefore, investigating cardiac function in COVID-19 is highly relevant, particularly in critically ill patients who are usually under sedation and mechanical ventilation, which may further impair cardiovascular function. Thus the objective is to determine the prevalence of left ventricle dysfunction and acute cor pulmonale, and its association with respiratory mechanics, in 100 consecutive critically ill COVID-19 patients, who were assessed with critical care echocardiography (CCE) within the first 24 hours of mechanical ventilation.
Description: Hypokinetic left ventricle function (left ventricle ejection fraction <45%)Measure: Percentage of patients with left ventricle dysfunction (hypokinetic) Time: 3 month
Description: Acute cor pulmonale was defined as a dilated right ventricle (right ventricle end-diastolic area/left ventricle end-diastolic area ratio >0.6) associated with the presence of paradoxical septum motionMeasure: Percentage of patients with acute cor pulmonale Time: 3 month
Description: Respiratory system compliance is defined as the change in lung volume (Tidal volume, ml) produced by a unit change in pulmonary pressure (driving pressure, cmH2O). The reported value of respiratory system compliance will be reported in ml/cmH2O.Measure: Differences in respiratory system compliance between patients with and without acute cor pulmonale Time: Within the first 24 hours of mechanical ventilation.
Description: Partial arterial pressure of carbon dioxide will be reported in mmHg.Measure: Differences in partial arterial pressure of carbon dioxide (PCO2) between patients with and without acute cor pulmonale Time: Within the first 24 hours of mechanical ventilation.
Description: PaO2/FiO2 ratio is the ratio of arterial oxygen partial pressure (PaO2 in mmHg) to fractional inspired oxygen (FiO2 expressed as a fraction). The reported value is a positive integer.Measure: Differences in PaO2/FiO2 ratio between patients with and without acute cor pulmonale Time: Within the first 24 hours of mechanical ventilation.
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports